| 2023-02-28 | +68.6% | legal | SEC EDGAR | BVS 8-K: 1.01 and 7.01 (SEC Filing) |
| 2022-11-08 | -61.9% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2022-11-16 | -38.9% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2024-05-07 | +25.9% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2024-11-05 | -21.5% | earnings | Seeking Alpha | Bioventus Inc. (BVS) Q3 2024 Earnings Call Transcript |
| 2024-11-05 | -21.5% | earnings | Seeking Alpha | Bioventus Inc. 2024 Q3 - Results - Earnings Call Presentation |
| 2024-11-05 | -21.5% | earnings | Seeking Alpha | Bioventus Non-GAAP EPS of $0.06, revenue of $139M beats by $5.76M |
| 2024-11-05 | -21.5% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2023-08-08 | +21.4% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2023-05-11 | +19.7% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2023-04-05 | +19.0% | legal | SEC EDGAR | BVS 8-K: 5.02 and (SEC Filing) |
| 2024-08-06 | +18.9% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2025-11-03 | +16.3% | earnings | Yahoo Finance | What To Expect From Bioventus Inc (BVS) Q3 2025 Earnings - Yahoo Finance |
| 2025-03-11 | +15.3% | earnings | Seeking Alpha | Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript |
| 2025-03-11 | +15.3% | earnings | Seeking Alpha | Bioventus Non-GAAP EPS of $0.15 beats by $0.07, revenue of $153.64M beats by $8.48M |
| 2025-03-11 | +15.3% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2025-11-04 | +13.3% | earnings | Seeking Alpha | Bioventus reiterates 2025 guidance with 6%–8% organic growth target as PNS and PRP launches gain traction |
| 2025-11-04 | +13.3% | earnings | Seeking Alpha | Bioventus Inc. (BVS) Q3 2025 Earnings Call Transcript |
| 2025-11-04 | +13.3% | earnings | Seeking Alpha | Bioventus surges on Q3 beats |
| 2025-11-04 | +13.3% | earnings | Seeking Alpha | Bioventus Non-GAAP EPS of $0.15 beats by $0.03, revenue of $138.7M beats by $0.51M |
| 2025-11-04 | +13.3% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2025-08-06 | +12.2% | earnings | Seeking Alpha | Bioventus Non-GAAP EPS of $0.21, revenue of $147.7M |
| 2025-08-06 | +12.2% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2022-06-29 | -11.7% | legal | SEC EDGAR | BVS 8-K: 5.02 (SEC Filing) |
| 2023-01-09 | -11.5% | legal | SEC EDGAR | BVS 8-K: 5.02 (SEC Filing) |
| 2026-04-14 | +10.1% | news | Simply Wall St. | ASX Penny Stocks To Watch In April 2026 |
| 2026-04-14 | +10.1% | news | Stock Titan | Bioventus (BVS) SVP gains 9,925 shares from RSU vesting, with tax withholding - Stock Titan |
| 2026-04-14 | +10.1% | earnings | MarketBeat | Bioventus (NASDAQ:BVS) Hits New 1-Year High - What's Next? - MarketBeat |
| 2026-04-14 | +10.1% | news | Stock Titan | [Form 4] Bioventus Inc. Insider Trading Activity - Stock Titan |
| 2026-04-14 | +10.1% | news | Stock Titan | Unaccepted RSU grant corrected for Bioventus (NASDAQ: BVS) director - Stock Titan |
| 2026-04-14 | +10.1% | executive | Stock Titan | Bioventus (BVS) CFO exercises 13,000 RSUs and withholds 5,648 shares for tax - Stock Titan |
| 2026-04-14 | +10.1% | news | Stock Titan | Bioventus (BVS) director amends filing on unaccepted 9,000 RSU grant - Stock Titan |
| 2025-01-03 | -9.4% | legal | SEC EDGAR | BVS 8-K: 2.01, 8.01 (SEC Filing) |
| 2023-05-26 | +9.3% | legal | SEC EDGAR | BVS 8-K: 2.01, 8.01 (SEC Filing) |
| 2021-11-22 | -9.1% | legal | SEC EDGAR | BVS 8-K: 1.01 and (SEC Filing) |
| 2021-07-29 | -9.0% | legal | SEC EDGAR | BVS 8-K: 1.01 and (SEC Filing) |
| 2021-07-29 | -9.0% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2023-03-31 | -8.4% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2022-05-10 | -7.7% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2026-04-13 | +7.2% | news | Zacks | Are Investors Undervaluing Bioventus (BVS) Right Now? |
| 2026-04-13 | +7.2% | news | Yahoo Finance | Are Investors Undervaluing Bioventus (BVS) Right Now? - Yahoo Finance |
| 2026-04-13 | +7.2% | news | Cổng thông tin điện tử tỉnh Lào Cai | Is Bioventus (BVS) Stock in a Downtrend | Price at $9.04, Down 0.22% - Volume Leaders - Cổng thông tin điện tử tỉnh Lào Cai |
| 2022-09-14 | -6.4% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Bioventus (BVS) - Zacks Investment Research |
| 2025-01-05 | -6.4% | news | Seeking Alpha | Bioventus: Amply Rewarded For Recent Progress |
| 2023-03-20 | +6.2% | news | Yahoo Finance | Are Options Traders Betting on a Big Move in Bioventus (BVS) Stock? - Yahoo Finance |
| 2023-05-16 | +6.0% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2023-05-16 | +6.0% | legal | SEC EDGAR | BVS 8-K: 1.01, 7.01 (SEC Filing) |
| 2021-10-29 | +5.9% | legal | SEC EDGAR | BVS 8-K: 1.01, 2.01, 2.03, 5.02, 7.01 (SEC Filing) |
| 2025-05-06 | -5.8% | earnings | Seeking Alpha | Bioventus reiterates 2025 guidance with focus on growth and profitability |
| 2025-05-06 | -5.8% | earnings | Seeking Alpha | Bioventus Inc. (BVS) Q1 2025 Earnings Call Transcript |
| 2025-05-06 | -5.8% | earnings | Seeking Alpha | Bioventus Non-GAAP EPS of $0.08 beats by $0.06, revenue of $123.88M beats by $1.17M |
| 2025-05-06 | -5.8% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2025-08-07 | -5.8% | earnings | Seeking Alpha | Bioventus Inc. 2025 Q2 - Results - Earnings Call Presentation |
| 2025-08-07 | -5.8% | earnings | Seeking Alpha | Bioventus outlines path to $100M+ PNS revenue opportunity as new products receive clearance |
| 2025-08-07 | -5.8% | earnings | Seeking Alpha | Bioventus Inc. (BVS) Q2 2025 Earnings Call Transcript |
| 2025-08-07 | -5.8% | executive | Stock Titan | Exclusive: Bioventus CEO Reveals Future Growth Plans at Major Healthcare Conference - Stock Titan |
| 2022-11-21 | -5.7% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2023-04-11 | -5.7% | legal | SEC EDGAR | BVS 8-K: 5.02 and (SEC Filing) |
| 2023-11-07 | +5.6% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2022-07-12 | -5.6% | legal | SEC EDGAR | BVS 8-K: 1.01, 2.01 (SEC Filing) |
| 2025-12-05 | -5.5% | news | Seeking Alpha | Bioventus Inc. (BVS) Presents at Piper Sandler 37th Annual Healthcare Conference - Slideshow |
| 2021-08-01 | -4.9% | earnings | Zacks Investment Research | What date does Bioventus's (BVS) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research |
| 2026-01-30 | +4.8% | legal | DirectorsTalk Interviews | Bioventus Inc. (BVS) Stock Analysis: Unveiling a Potential 91.82% Upside in the Medical Device Sector - DirectorsTalk Interviews |
| 2021-08-30 | -4.4% | legal | SEC EDGAR | BVS 8-K: 8.01 (SEC Filing) |
| 2021-08-25 | +4.2% | legal | SEC EDGAR | BVS 8-K: 8.01 (SEC Filing) |
| 2024-10-04 | -4.1% | legal | SEC EDGAR | BVS 8-K: 1.01, 8.01 (SEC Filing) |
| 2026-01-14 | +4.0% | news | Seeking Alpha | Bioventus Inc. (BVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript |
| 2026-01-14 | +4.0% | news | Yahoo Finance | Institutional investors own a significant stake of 36% in Bioventus Inc. (NASDAQ:BVS) - Yahoo Finance |
| 2022-02-28 | +3.9% | legal | SEC EDGAR | BVS 8-K: 5.02 and (SEC Filing) |
| 2024-07-19 | +3.7% | legal | SEC EDGAR | BVS 8-K: 8.01 (SEC Filing) |
| 2026-01-10 | -3.6% | news | simplywall.st | Recent uptick might appease Bioventus Inc. (NASDAQ:BVS) institutional owners after losing 13% over the past year - simplywall.st |
| 2025-07-31 | -3.5% | legal | SEC EDGAR | BVS 8-K: 8.01 and (SEC Filing) |
| 2022-06-22 | -3.5% | legal | SEC EDGAR | BVS 8-K: 1.01 and (SEC Filing) |
| 2021-11-17 | -3.4% | legal | SEC EDGAR | BVS 8-K: 5.02 (SEC Filing) |
| 2022-08-11 | +3.2% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2025-11-17 | -3.1% | legal | SEC EDGAR | BVS 8-K: 5.02 (SEC Filing) |
| 2025-04-14 | +2.8% | news | Intellectia AI | BVS Forecast — Price Prediction for 2026. Should I Buy BVS? - Intellectia AI |
| 2022-03-10 | +2.5% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2024-10-25 | -2.4% | legal | Seeking Alpha | Bioventus files for $200M mixed securities shelf |
| 2026-01-15 | +2.3% | news | Seeking Alpha | Bioventus Inc. (BVS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow |
| 2026-02-17 | +2.0% | news | Intellectia AI | BVS Should I Buy - Intellectia AI |
| 2026-04-06 | -2.0% | earnings | MarketBeat | Bioventus Inc. (NASDAQ:BVS) Given Consensus Rating of "Buy" by Brokerages - MarketBeat |
| 2021-05-12 | +2.0% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2021-07-14 | -1.9% | legal | SEC EDGAR | BVS 8-K: 5.02 (SEC Filing) |
| 2022-08-30 | -1.8% | analyst | TradingView | BVS Forecast — Price Target — Prediction for 2027 - TradingView |
| 2026-04-16 | -1.8% | news | Zacks | Strength Seen in Bioventus (BVS): Can Its 6.6% Jump Turn into More Strength? |
| 2026-04-16 | -1.8% | news | Yahoo Finance | Strength Seen in Bioventus (BVS): Can Its 6.6% Jump Turn into More Strength? - Yahoo Finance |
| 2021-10-18 | +1.8% | legal | SEC EDGAR | BVS 8-K: 8.01 (SEC Filing) |
| 2021-12-27 | -1.8% | legal | SEC EDGAR | BVS 8-K: 5.02 (SEC Filing) |
| 2023-06-09 | -1.8% | legal | SEC EDGAR | BVS 8-K: 5.02, 5.07 (SEC Filing) |
| 2025-08-04 | -1.7% | expansion | Seeking Alpha | Bioventus enters into a new $400M credit agreement, lowering interest expenses |
| 2025-08-04 | -1.7% | legal | SEC EDGAR | BVS 8-K: 1.01, 2.03 (SEC Filing) |
| 2026-03-24 | +1.6% | executive | Stock Titan | Bioventus (BVS) CFO vests 18,625 RSUs with 8,091 shares withheld for taxes - Stock Titan |
| 2025-01-07 | -1.6% | executive | Stock Titan | Bioventus CEO to Present at J.P. Morgan Healthcare Conference 2025 - Stock Titan |
| 2025-11-07 | -1.5% | earnings | Seeking Alpha | Bioventus Inc. 2025 Q3 - Results - Earnings Call Presentation |
| 2022-04-26 | -1.5% | legal | SEC EDGAR | BVS 8-K: 2.02, 7.01, 8.01 (SEC Filing) |
| 2022-01-12 | -1.5% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2022-04-04 | +1.4% | legal | SEC EDGAR | BVS 8-K: 8.01 (SEC Filing) |
| 2021-08-10 | +1.4% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2024-03-12 | -1.3% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2026-03-05 | +1.2% | earnings | MarketBeat | Bioventus Q4 Earnings Call Highlights |
| 2026-03-05 | +1.2% | earnings | GuruFocus.com | Bioventus Inc (BVS) Q4 2025 Earnings Call Highlights: Strong Organic Growth and Strategic ... |
| 2026-03-05 | +1.2% | earnings | Moby | Bioventus Inc. Q4 2025 Earnings Call Summary |
| 2026-03-05 | +1.2% | earnings | Motley Fool | Bioventus (BVS) Q4 2025 Earnings Call Transcript |
| 2026-03-05 | +1.2% | earnings | Associated Press Finance | Bioventus: Q4 Earnings Snapshot |
| 2026-03-05 | +1.2% | news | GlobeNewswire | Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results |
| 2026-03-05 | +1.2% | news | Seeking Alpha | Bioventus outlines $600M–$610M 2026 sales target with accelerated investment in PNS, PRP, and ultrasonics |
| 2026-03-05 | +1.2% | earnings | Seeking Alpha | Bioventus Inc. (BVS) Q4 2025 Earnings Call Transcript |
| 2026-03-05 | +1.2% | earnings | Seeking Alpha | Bioventus Inc. 2025 Q4 - Results - Earnings Call Presentation |
| 2026-03-05 | +1.2% | earnings | Seeking Alpha | Bioventus Non-GAAP EPS of $0.24 beats by $0.02, revenue of $157.9M beats by $2.95M |
| 2026-03-05 | +1.2% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2026-03-05 | +1.2% | earnings | Quiver Quantitative | BIOVENTUS ($BVS) Releases Q4 2025 Earnings | BVS Stock News - Quiver Quantitative |
| 2026-03-26 | +1.1% | earnings | Simply Wall St. | How The Bravura Solutions (ASX:BVS) Story Is Shifting On Earnings Guidance And Dividend Moves |
| 2023-03-06 | -1.0% | news | GlobeNewswire | BIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION - GlobeNewswire |
| 2025-09-10 | -1.0% | news | Seeking Alpha | Bioventus Inc. (BVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript |
| 2025-12-02 | -0.9% | news | Seeking Alpha | Bioventus: A New Start |
| 2024-01-19 | -0.8% | legal | SEC EDGAR | BVS 8-K: 1.01 and (SEC Filing) |
| 2023-12-21 | -0.8% | legal | SEC EDGAR | BVS 8-K: 5.02, 7.01 (SEC Filing) |
| 2021-11-09 | +0.6% | legal | SEC EDGAR | BVS 8-K: 2.02 and (SEC Filing) |
| 2024-06-21 | +0.6% | legal | SEC EDGAR | BVS 8-K: 1.01 and (SEC Filing) |
| 2026-02-27 | -0.6% | news | DirectorsTalk Interviews | Bioventus Inc. (BVS) Stock Analysis: Unpacking A 63.66% Potential Upside - DirectorsTalk Interviews |
| 2026-03-28 | +0.6% | news | Cổng thông tin điện tử Tỉnh Sơn La | What is market pressure on Bioventus (BVS) Stock | Price at $9.06, Up 0.06% - Expert Verified Trades - Cổng thông tin điện tử Tỉnh Sơn La |
| 2026-02-24 | -0.5% | earnings | Stock Titan | Bioventus sets March 5 call, Q4 2025 earnings and business update - Stock Titan |
| 2022-09-01 | +0.5% | legal | SEC EDGAR | BVS 8-K: 5.02 (SEC Filing) |
| 2024-03-27 | +0.3% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2025-08-09 | +0.3% | earnings | simplywall.st | Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st |
| 2024-01-12 | -0.3% | legal | SEC EDGAR | BVS 8-K: 5.02 (SEC Filing) |
| 2025-01-31 | -0.2% | news | Yahoo Finance | With 32% ownership, Bioventus Inc. (NASDAQ:BVS) has piqued the interest of institutional investors - Yahoo Finance |
| 2025-07-30 | +0.2% | legal | Seeking Alpha | Bioventus gets FDA nod for pain management devices |
| 2026-04-22 | +0.1% | executive | Quiver Quantitative | Bioventus Inc. ($BVS) CEO 2025 Pay Revealed - Quiver Quantitative |
| 2026-04-22 | +0.1% | news | Stock Titan | Bioventus (NASDAQ: BVS) sets 2026 virtual meeting, director slate and auditor vote - Stock Titan |
| 2023-03-03 | -0.0% | legal | SEC EDGAR | BVS 8-K: 2.01 and (SEC Filing) |